cas 22809-37-6|| where to buy 6-Bromohexanoyl chloride

Название продукции:6-Bromohexanoyl chloride

IUPAC Name:6-bromohexanoyl chloride

Упаковочная единица	Доступно для заказа	Цена ($)
CM343221-25g	1-2 Weeks	Ʊȷ
CM343221-100g	3-4 Weeks	ɅȦǧ

Только для использования в НИОКР..

Форма запроса

Химическое название

Номер CAS

Количество*

Необходимые спецификации*
(% пробы, категория материала и т.д.)

Контактное лицо*

Электронная почта*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 22809-37-6 regularly via the above email.

Дополнительные примечания

Verification code*

refresh

: Номер CAS:22809-37-6; Молекулярная формула:C6H10BrClO; Точка плавления:-; Smiles-код:O=C(Cl)CCCCCBr; Плотность:

: Номер в каталоге:CM343221; Молекулярная масса:213.5; Точка кипения:; Номер Mdl:MFCD00000761; Хранение:

: Aliphatic Chain Compounds; Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

: Naronapride; FDA approved an Investigational New Drug (IND) application for Naronapride to treat PPI-non-responsive symptomatic gastroesophageal reflux disease (GERD) .
Naronapride is a potential best-in-class oral, locally acting pan-GI prokinetic, which works by modulating two validated targets on the luminal surface of the intestinal wall, 5-HT4 receptor agonism and D2 receptor antagonism, with a well-differentiated pharmaceutical, pharmacokinetics, safety, and efficacy profile from other 5-HT4 agonists.